Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

zimmer biomet holdings inc. - ZBH

ZBH

Close Chg Chg %
89.15 -0.56 -0.63%

Closed Market

88.59

-0.56 (0.63%)

Volume: 2.27M

Last Updated:

Mar 27, 2026, 3:59 PM EDT

Trade Now

Company Overview: zimmer biomet holdings inc. - ZBH

ZBH Key Data

Open

$88.61

 Day Range

87.64 - 89.38

52 Week Range

84.59 - 114.44

 Market Cap

$17.44B

Shares Outstanding

195.65M

 Public Float

195.36M

Beta

0.59

 Rev. Per Employee

N/A

P/E Ratio

25.12

 EPS

$3.56

Yield

107.68%

 Dividend

$0.24

EX-DIVIDEND DATE

Mar 31, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.08M

  

ZBH Performance

1 Week
 
 0.80%
 
1 Month
 
 -10.03%
 
3 Months
 
 -2.42%
 
1 Year
 
 -21.10%
 
5 Years
 
 -43.97%
 

ZBH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About zimmer biomet holdings inc. - ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

ZBH At a Glance

Zimmer Biomet Holdings, Inc.
345 East Main Street
Warsaw, Indiana 46580
Phone 1-574-373-3333 Revenue 8.23B
Industry Medical Specialties Net Income 705.10M
Sector Health Technology 2025 Sales Growth 7.201%
Fiscal Year-end 12 / 2026 Employees 17,000
View SEC Filings

ZBH Valuation

P/E Current 25.123
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.34
Price to Sales Ratio 2.171
Price to Book Ratio 1.384
Price to Cash Flow Ratio 10.53
Enterprise Value to EBITDA 10.36
Enterprise Value to Sales 3.041
Total Debt to Enterprise Value 0.31

ZBH Efficiency

Revenue/Employee 484,205.882
Income Per Employee 41,476.471
Receivables Turnover 4.83
Total Asset Turnover 0.37

ZBH Liquidity

Current Ratio 1.982
Quick Ratio 1.097
Cash Ratio 0.229

ZBH Profitability

Gross Margin 60.934
Operating Margin 16.07
Pretax Margin 10.093
Net Margin 8.566
Return on Assets 3.172
Return on Equity 5.604
Return on Total Capital 3.448
Return on Invested Capital 3.73

ZBH Capital Structure

Total Debt to Total Equity 61.051
Total Debt to Total Capital 37.908
Total Debt to Total Assets 33.571
Long-Term Debt to Equity 55.975
Long-Term Debt to Total Capital 34.756
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Zimmer Biomet Holdings Inc. - ZBH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
6.94B 7.39B 7.68B 8.23B
Sales Growth
-11.44% +6.55% +3.85% +7.20%
Cost of Goods Sold (COGS) incl D&A
2.60B 2.73B 2.86B 3.22B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
926.40M 951.70M 996.30M 1.09B
Depreciation
399.60M 390.20M 404.40M 427.90M
Amortization of Intangibles
526.80M 561.50M 591.90M 665.90M
COGS Growth
-12.00% +5.00% +4.60% +12.56%
Gross Income
4.34B 4.66B 4.82B 5.02B
Gross Income Growth
-11.10% +7.47% +3.40% +4.03%
Gross Profit Margin
+62.52% +63.06% +62.79% +60.93%
2022 2023 2024 2025 5-year trend
SG&A Expense
3.10B 3.28B 3.34B 3.69B
Research & Development
406.00M 458.70M 437.40M 458.50M
Other SG&A
2.70B 2.82B 2.90B 3.23B
SGA Growth
-14.51% +5.62% +1.85% +10.68%
Other Operating Expense
- - - 33.80M
-
Unusual Expense
703.30M 201.70M 326.40M 271.70M
EBIT after Unusual Expense
499.90M 1.19B 1.16B 1.05B
Non Operating Income/Expense
67.70M 77.30M 85.10M 63.80M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
164.10M 195.30M 207.10M 284.10M
Interest Expense Growth
-21.03% +19.01% +6.04% +37.18%
Gross Interest Expense
164.10M 195.30M 207.10M 284.10M
Interest Capitalized
- - - -
-
Pretax Income
403.50M 1.07B 1.04B 830.80M
Pretax Income Growth
-3.56% +164.51% -2.88% -19.85%
Pretax Margin
+5.81% +14.43% +13.50% +10.09%
Income Tax
112.30M 42.20M 131.40M 125.70M
Income Tax - Current - Domestic
191.40M 20.00M 25.30M 84.40M
Income Tax - Current - Foreign
(14.70M) 118.50M 153.80M 128.50M
Income Tax - Deferred - Domestic
(73.20M) (141.90M) (72.00M) (151.70M)
Income Tax - Deferred - Foreign
8.80M 45.60M 24.30M 64.50M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (100.00K)
-
Consolidated Net Income
291.20M 1.03B 905.20M 705.00M
Minority Interest Expense
1.00M 1.10M 1.50M (100.00K)
Net Income
290.20M 1.02B 903.70M 705.10M
Net Income Growth
-27.74% +252.86% -11.75% -21.98%
Net Margin Growth
+4.18% +13.85% +11.77% +8.57%
Extraordinaries & Discontinued Operations
- - - (58.80M)
-
Discontinued Operations
- - - (58.80M)
-
Net Income After Extraordinaries
231.40M 1.02B 903.70M 705.10M
Preferred Dividends
- - - -
-
Net Income Available to Common
231.40M 1.02B 903.80M 705.10M
EPS (Basic)
1.104 4.9066 4.45 3.5611
EPS (Basic) Growth
-42.66% +344.44% -9.31% -19.98%
Basic Shares Outstanding
209.60M 208.70M 203.10M 198.00M
EPS (Diluted)
1.1003 4.8832 4.4326 3.5486
EPS (Diluted) Growth
-42.36% +343.81% -9.23% -19.94%
Diluted Shares Outstanding
210.30M 209.70M 203.90M 198.70M
EBITDA
2.13B 2.34B 2.48B 2.42B
EBITDA Growth
-6.04% +9.82% +6.10% -2.61%
EBITDA Margin
+30.69% +31.63% +32.31% +29.36%

Snapshot

Average Recommendation HOLD Average Target Price 101.619
Number of Ratings 29 Current Quarters Estimate 1.864
FY Report Date 03 / 2026 Current Year's Estimate 8.399
Last Quarter’s Earnings 2.42 Median PE on CY Estimate N/A
Year Ago Earnings 8.20 Next Fiscal Year Estimate 9.014
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 25 26 24
Mean Estimate 1.86 2.05 8.40 9.01
High Estimates 1.91 2.14 8.48 9.75
Low Estimate 1.84 1.96 8.35 8.63
Coefficient of Variance 1.04 1.86 0.37 2.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 9 7
OVERWEIGHT 0 1 2
HOLD 18 18 20
UNDERWEIGHT 1 1 0
SELL 2 3 2
MEAN Hold Hold Hold

Insider Actions for Zimmer Biomet Holdings Inc. - ZBH

Date Name Shares Transaction Value
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Wilfred van Zuilen Group Pres, EMEA N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Paul Stellato VP, Controller, CAO 5,582 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.54 per share 516,558.28
Mar 11, 2026 Paul Stellato VP, Controller, CAO 5,864 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Paul Stellato VP, Controller, CAO 5,257 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.54 per share 486,482.78
Mar 11, 2026 Paul Stellato VP, Controller, CAO 5,890 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Sang Yi Group President, Asia Pacific N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Sang Yi Group President, Asia Pacific N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Sang Yi Group President, Asia Pacific 32,251 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Sang Yi Group President, Asia Pacific 29,887 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Chad F. Phipps See remarks below. 68,398 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO 69,485 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.54 per share 6,430,141.90
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO 71,514 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO 66,955 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.54 per share 6,196,015.70
Mar 11, 2026 Suketu P. Upadhyay Exec VP, CFO 71,502 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Chad F. Phipps See remarks below. N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Chad F. Phipps See remarks below. N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Chad F. Phipps See remarks below. 67,760 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.54 per share 6,270,510.40
Mar 11, 2026 Chad F. Phipps See remarks below. 68,603 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Zimmer Biomet Holdings Inc. in the News